elranatamab
pfizer
['magnetismm-3', 'mmsm', 'multiple myeloma', 'elranatamab']
#ash22 #mmsm elranatamab- magnetismm-3 (cohort a) 11% discontinuation for aes treatment disposition orr of 61% 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities